Presentation is loading. Please wait.

Presentation is loading. Please wait.

Treatment and secondary prevention strategy diagram for VTE in patients with active cancer based on the treatment guidelines for cancer-associated VTE.

Published byEirik Øverland Modified over 5 years ago

Similar presentations

Presentation on theme: "Treatment and secondary prevention strategy diagram for VTE in patients with active cancer based on the treatment guidelines for cancer-associated VTE."— Presentation transcript:

1 Treatment and secondary prevention strategy diagram for VTE in patients with active cancer based on the treatment guidelines for cancer-associated VTE. DOAC, direct oral anticoagulant; LMWH, low-molecular-weight heparin; VKA, vitamin K antagonist; VTE, venous thromboembolism. aThere is an evidence gap regarding which dose of LMWH to choose for extended therapy beyond 6 months; in clinical practice, some experts continue with full therapeutic dose and others reduce to a prophylactic dose. Treatment and secondary prevention strategy diagram for VTE in patients with active cancer based on the treatment guidelines for cancer-associated VTE. DOAC, direct oral anticoagulant; LMWH, low-molecular-weight heparin; VKA, vitamin K antagonist; VTE, venous thromboembolism. aThere is an evidence gap regarding which dose of LMWH to choose for extended therapy beyond 6 months; in clinical practice, some experts continue with full therapeutic dose and others reduce to a prophylactic dose. Cihan Ay et al. ESMO Open 2017;2:e000188 Copyright © European Society for Medical Oncology. All rights reserved.

Download ppt "Treatment and secondary prevention strategy diagram for VTE in patients with active cancer based on the treatment guidelines for cancer-associated VTE."

Similar presentations

Venous thromboembolism: how long to treat?

Venous thromboembolism: how long to treat?
Thalidomide-based Regimens: Rates of VTE* in Newly Diagnosed MM Treatment No Prophylaxis Any Prophylaxis ASA Warfarin 1-1.25 mg/d Prophylactic LMWH Therapeutic.

Thalidomide-based Regimens: Rates of VTE* in Newly Diagnosed MM Treatment No Prophylaxis Any Prophylaxis ASA Warfarin mg/d Prophylactic LMWH Therapeutic.
Fundamental Research in Oncology & Thrombosis FRONTLINE 1 Survey.

Fundamental Research in Oncology & Thrombosis FRONTLINE 1 Survey.
Clinical Professor in Palliative Medicine

Clinical Professor in Palliative Medicine
Volume 130, Issue 6, Pages (December 2006)

Volume 130, Issue 6, Pages (December 2006)
Copyright © 2003 American Medical Association. All rights reserved.

Copyright © 2003 American Medical Association. All rights reserved.
Copyright © 2000 American Medical Association. All rights reserved.

Copyright © 2000 American Medical Association. All rights reserved.
NOACs In Long-term VTE Treatment: A State Of The Art Review

NOACs In Long-term VTE Treatment: A State Of The Art Review
The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.

The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.
Prevention and Management of Venous Thromboembolic Events in Patients With Multiple Myeloma.

Prevention and Management of Venous Thromboembolic Events in Patients With Multiple Myeloma.
A Better Solution For Cancer Patients With VTE?

A Better Solution For Cancer Patients With VTE?
Forest plot of the HRs for DOACs vs warfarin for (A) new or recurrent VTE and (B) major bleeding based on the published subanalyses of the patients with.

Forest plot of the HRs for DOACs vs warfarin for (A) new or recurrent VTE and (B) major bleeding based on the published subanalyses of the patients with.
Caprini venous thromboembolism risk assessment permits selection for postdischarge prophylactic anticoagulation in patients with resectable lung cancer 

Caprini venous thromboembolism risk assessment permits selection for postdischarge prophylactic anticoagulation in patients with resectable lung cancer 
Succinct Review of the New VTE Prevention and Management Guidelines

Succinct Review of the New VTE Prevention and Management Guidelines
Cancer-Associated Thrombosis

Cancer-Associated Thrombosis
(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.

(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.
by Alex C. Spyropoulos, and James D. Douketis

by Alex C. Spyropoulos, and James D. Douketis
Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.

Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.
Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.

Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.
Flow chart of the used methodology adapted from Moher et al

Flow chart of the used methodology adapted from Moher et al

Similar presentations

Ads by Google